Wyrick Robbins Client to Ring NASDAQ Closing Bell
RALEIGH, NC—Wyrick Robbins is pleased to announce that its client Ventrus Biosciences, Inc.(NASDAQ: VTUS) will ring the NASDAQ Closing Bell on Thursday, May 19, 2011, in celebration of the company’s listing.
Wyrick Robbins represented Ventrus throughout the initial public offering process last year. Firm attorneys W. David Mannheim and Alec M. Donaldson will accompany Ventrus at the ceremony.
“Achieving a successful initial public offering and national exchange listing in the tough investment environment of 2010 is a testament to the quality of Ventrus’ management team and the potential of its product candidates. We are honored to be included in the NASDAQ celebration,” says Wyrick Robbins partners David Mannheim and Alec Donaldson.
A live webcast of Ventrus Biosciences, Inc. ringing the NASDAQ Closing Bell will be available at 3:45 p.m. EST on May 19, 2011, here.
About Ventrus Biosciences, Inc.
Ventrus is a development stage specialty pharmaceutical company focused on the development of late-stage prescription drugs for gastrointestinal disorders. The company’s lead product is Iferanserin (VEN 309) for the topical treatment of hemorrhoids. An additional product candidate portfolio consists of two in-licensed late-stage drugs intended to treat anal fissures (VEN 307) and fecal incontinence (VEN 308). The first Phase III clinical trial with VEN 307 has begun in Europe and data is expected to be available in the second quarter of 2012. These candidates are two molecules that were previously approved and marketed for other indications and that have been formulated into our proprietary topical treatments for these new gastrointestinal indications.
About Wyrick Robbins
Wyrick Robbins is an entrepreneurial law firm with a focus on growth-oriented businesses. The firm handles financial and corporate transactions and complex commercial litigation as well as other legal needs of dynamic companies. In addition, Wyrick Robbins lawyers serve as trusted advisors to founders, investors, directors, and management.
For more information:
Jennifer Herendeen
jherendeen@wyrick.com
919.781.4000